

**Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up**

<b>Rs. Mio.</b>	<b>Q4 11-12</b>	<b>Q4 10-11</b>	<b>% Gr y-y</b>	<b>FY 11-12</b>	<b>FY 10-11</b>	<b>% Gr y-y</b>
<b>Domestic</b>	<b>6,443</b>	<b>4,864</b>	<b>32.5%</b>	<b>24,546</b>	<b>21,387</b>	<b>14.8%</b>
Formulations	4,988	3,610	38.2%	18,954	16,208	16.9%
APIs	147	121	21.5%	438	352	24.4%
Wellness	857	775	10.6%	3,446	3,355	2.7%
Animal Health & Others	451	358	25.8%	1,708	1,472	16.1%
<b>Exports</b>	<b>6,209</b>	<b>5,291</b>	<b>17.3%</b>	<b>23,031</b>	<b>20,179</b>	<b>14.1%</b>
Formulations	5,486	4,640	18.2%	20,298	17,063	19.0%
US	3,533	2,803	26.1%	12,431	9,655	28.7%
Europe	706	656	7.7%	2,983	2,755	8.3%
Japan	136	130	5.0%	522	422	23.8%
Brazil	556	525	5.9%	2,473	2,250	9.9%
Emerging Markets	555	528	5.2%	1,889	1,980	-4.6%
APIs	597	650	-8.2%	2,416	3,116	-22.5%
Animal Health & Others	125	0		316	0	
<b>JVs</b>	<b>1141</b>	<b>1689</b>	<b>-32.4%</b>	<b>4230</b>	<b>3645</b>	<b>16.0%</b>
<b>Total</b>	<b>13,793</b>	<b>11,844</b>	<b>16.5%</b>	<b>51,807</b>	<b>45,211</b>	<b>14.6%</b>

**Cadila Healthcare Ltd. - Details of other incomes**

Rs. Mio.	Q4 11-12	Q4 10-11	% Gr y-y	FY 11-12	FY 10-11	% Gr y-y
<b>Other Operating Income</b>	<b>536</b>	<b>446</b>	<b>20.2%</b>	<b>1,733</b>	<b>1,659</b>	<b>4.5%</b>
Dossier Fees	18	7	157.1%	513	498	3.0%
Royalty Income	143	81	76.5%	356	299	19.1%
Govt. Grants	21	1	2000.0%	21	24	-12.5%
Others	354	357	-0.8%	843	838	0.6%

Rs. Mio.	Q4 11-12	Q4 10-11	% Gr y-y	FY 11-12	FY 10-11	% Gr y-y
<b>Other Income</b>	<b>176</b>	<b>35</b>	<b>402.9%</b>	<b>531</b>	<b>131</b>	<b>305.3%</b>
Interest & Dividend income	108	28	285.7%	333	120	177.5%
Profit on sale of investments	1	1	-11.9%	60	1	5900.0%
Profit on sale of assets	-8	0		0	0	
Others	75	6	1152.0%	138	10	1280.0%

**Details of R&D Expenses**

Rs. Mio.	Q4 11-12	Q4 10-11	% Gr y-y	YTD 11-12	YTD 10-11	% Gr y-y
Salary	165	143	15%	713	515	38%
Others	726	556	31%	2,925	1,988	47%
<b>Total</b>	<b>891</b>	<b>699</b>	<b>27%</b>	<b>3,638</b>	<b>2,503</b>	<b>45%</b>

Consolidated Capex for FY 11-12 :

**Rs. 6495 Mio.**

R&D capex included in above for FY 11-12 :

**Rs. 423 Mio.**